These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 28976433)
1. T-Score Discordance of Bone Mineral Density in Patients with Atypical Femoral Fracture. Lee KJ; Min BW; Song KS; Bae KC; Cho CH; Lee SW J Bone Joint Surg Am; 2017 Oct; 99(19):1683-1688. PubMed ID: 28976433 [TBL] [Abstract][Full Text] [Related]
2. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy. Clout A; Narayanasamy N; Harris I J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510 [TBL] [Abstract][Full Text] [Related]
3. Trabecular Bone Score and Hip Structural Analysis in Patients With Atypical Femur Fractures. Buitendijk SKC; van de Laarschot DM; Smits AAA; Koromani F; Rivadeneira F; Beck TJ; Zillikens MC J Clin Densitom; 2019; 22(2):257-265. PubMed ID: 29661684 [TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case-Cohort Study With Blinded Radiographic Review. Bauer DC; Black DM; Dell R; Fan B; Smith CD; Ernst MT; Jurik AG; Frøkjær JB; Boesen M; Vittinghoff E; Abrahamsen B J Clin Endocrinol Metab; 2024 Oct; 109(11):e2141-e2150. PubMed ID: 38198798 [TBL] [Abstract][Full Text] [Related]
5. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078 [TBL] [Abstract][Full Text] [Related]
6. Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea. Lee YK; Ahn S; Kim KM; Suh CS; Koo KH J Korean Med Sci; 2018 Jan; 33(5):e38. PubMed ID: 29349947 [TBL] [Abstract][Full Text] [Related]
7. Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population. Cho YJ; Kang KC; Chun YS; Rhyu KH; Kim SJ; Jang TS Arch Osteoporos; 2018 May; 13(1):53. PubMed ID: 29725835 [TBL] [Abstract][Full Text] [Related]
8. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study. Koh JH; Myong JP; Jung SM; Lee J; Kwok SK; Park SH; Ju JH Arthritis Rheumatol; 2016 Jan; 68(1):77-82. PubMed ID: 26360133 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis. Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy. Franceschetti P; Bondanelli M; Caruso G; Ambrosio MR; Lorusso V; Zatelli MC; Massari L; Degli Uberti EC Bone; 2013 Oct; 56(2):426-31. PubMed ID: 23871850 [TBL] [Abstract][Full Text] [Related]
11. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957 [TBL] [Abstract][Full Text] [Related]
12. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study. Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975 [TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates and the risk of atypical femur fractures. Black DM; Condra K; Adams AL; Eastell R Bone; 2022 Mar; 156():116297. PubMed ID: 34920168 [TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center. Bareli N; Gat R; Makarov V; Siris E; Fraenkel M; Yoel U Arch Osteoporos; 2021 Jun; 16(1):86. PubMed ID: 34089098 [TBL] [Abstract][Full Text] [Related]
15. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users. Lee SH; Lee YH; Suh JS AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551 [TBL] [Abstract][Full Text] [Related]
16. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. Lo JC; Neugebauer RS; Ettinger B; Chandra M; Hui RL; Ott SM; Grimsrud CD; Izano MA BMC Musculoskelet Disord; 2020 Dec; 21(1):801. PubMed ID: 33272248 [TBL] [Abstract][Full Text] [Related]
17. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review. Nasomyont N; Hornung LN; Gordon CM; Wasserman H Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029 [TBL] [Abstract][Full Text] [Related]
18. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Lo JC; Hui RL; Grimsrud CD; Chandra M; Neugebauer RS; Gonzalez JR; Budayr A; Lau G; Ettinger B Bone; 2016 Apr; 85():142-7. PubMed ID: 26769007 [TBL] [Abstract][Full Text] [Related]
19. Audit of Atypical Femoral Fractures and a Description of Some of Their Features. Lian K; Trollip J; Sandhu S; Moosavi M; Gill A; Kendler D; Dian L; Lentle B Can Assoc Radiol J; 2016 Feb; 67(1):69-75. PubMed ID: 26800621 [TBL] [Abstract][Full Text] [Related]
20. Frequency and associated factor of atypical periprosthetic femoral fracture after hip arthroplasty. Lee YK; Park CH; Kim KC; Hong SH; Ha YC; Koo KH Injury; 2018 Dec; 49(12):2264-2268. PubMed ID: 30245278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]